MODERN METHODS OF TREATMENT OF BACTERIAL VAGINOSIS IN WOMEN

Authors:

Abstract:

With the purpose to compare the effectiveness of different treatment regimens for bacterial vaginosis 67 patients with bacterial vaginosis detected by vaginal microscopy (age 18–45 years) were observed: 32 patients who received therapy by preparation based on neomycin sulfate, ornidazole, prednisolone sodium phosphate and econazole nitrate; 35 patients who received therapy with intravaginal metronidazole in gel form. The highest clinical efficacy (93.7 % according to R. Amsel criteria) was observed in patients of the group who received combination therapy (neomycin sulfate, ornidazole, prednisolone sodium phosphate and econazole nitrate; p<0.05) in contrast to metronidazole for vaginal use, which showed a result of 45.7 % according to R. Amsel criteria and provoked candidal vulvovaginitis in 20.0 % of cases. Thus, the use of the combined preparation, which has antibacterial, antiprotozoal, antifungal and anti-inflammatory action, in patients with bacterial vaginosis made it possible to achieve high clinical treatment efficacy and did not lead to candidal vulvovaginitis.

Keywords:

bacterial vaginosis Amsel criteria combined treatment intravaginal metronidazole candidal vulvovaginitis

References:

1. Abou Chacra L, Fenollar F, Diop K. Bacterial Vaginosis: What Do We Currently Know? Front Cell Infect Microbiol. 2022 Jan 18;11:672429. doi: 10.3389/fcimb.2021.672429.
2. Chen X, Lu Y, Chen T, Li R. The Female Vaginal Microbiome in Health and Bacterial Vaginosis. Front Cell Infect Microbiol. 2021 Apr 7;11:631972. doi: 10.3389/fcimb.2021.631972.
3. Faught BM, Reyes S. Characterization and Treatment of Recurrent Bacterial Vaginosis. J Womens Health (Larchmt). 2019 Sep;28(9):1218-1226. doi: 10.1089/jwh.2018.7383.
4. Han Y, Liu Z, Chen T. Role of Vaginal Microbiota Dysbiosis in Gynecological Diseases and the Potential Interventions. Front Microbiol. 2021 Jun 18;12:643422. doi: 10.3389/fmicb.2021.643422.
5. Javed A, Parvaiz F, Manzoor S. Bacterial vaginosis: An insight into the prevalence, alternative treatments regimen and it's associated resistance patterns. Microb Pathog. 2019 Feb;127:21-30. doi: 10.1016/j.micpath.2018.11.046.
6. Muzny CA, Kardas P. A Narrative Review of Current Challenges in the Diagnosis and Management of Bacterial Vaginosis. Sex Transm Dis. 2020 Jul;47(7):441-446. doi: 10.1097/OLQ.0000000000001178.
7. Muzny CA, Sobel JD. The Role of Antimicrobial Resistance in Refractory and Recurrent Bacterial Vaginosis and Current Recommendations for Treatment. Antibiotics (Basel). 2022 Apr 9;11(4):500. doi: 10.3390/antibiotics11040500.
8. Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. Sex Transm Dis. 2019 May;46(5):304-311. doi: 10.1097/OLQ.0000000000000972.
9. Song SD, Acharya KD, Zhu JE, Deveney CM, Walther-Antonio MRS, Tetel MJ, et al. Daily Vaginal Microbiota Fluctuations Associated with Natural Hormonal Cycle, Contraceptives, Diet, and Exercise. mSphere. 2020 Jul 8;5(4):e00593-20. doi: 10.1128/mSphere.00593-20.
10. Swidsinski S, Moll WM, Swidsinski A. Bacterial Vaginosis-Vaginal Polymicrobial Biofilms and Dysbiosis. Dtsch Arztebl Int. 2023 May 19;120(20):347-354. doi: 10.3238/arztebl.m2023.0090.
11. Vodstrcil LA, Muzny CA, Plummer EL, Sobel JD, Bradshaw CS. Bacterial vaginosis: drivers of recurrence and challenges and opportunities in partner treatment. BMC Med. 2021 Sep 2;19(1):194. doi: 10.1186/s12916-021-02077-3.

Publication:

«World of Medicine and Biology» Vol. 21 No. 91 (2025) , с. 11-15
УДК 618.15-002-017

DOI:

https://doi.org/10.26724/2079-8334-2025-1-91-11-15